

Table 1.21
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2009^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			34-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 34 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 34 Years ^d
All Sites	Both Sexes	4,357,341	4,442,261	4,864,827	12,096,978	12,304,118
	Male	2,246,570	2,279,828	2,484,619	5,717,465	5,784,750
	Female	2,110,771	2,162,433	2,380,208	6,379,513	6,519,368
Oral Cavity & Pharynx	Both Sexes	97,542	111,817	115,695	252,887	278,231
	Male	67,675	76,701	79,161	166,069	180,884
	Female	29,867	35,116	36,534	86,818	97,347
Esophagus	Both Sexes	20,356	24,677	24,737	31,710	37,085
	Male	15,922	19,308	19,356	24,602	28,647
	Female	4,434	5,369	5,381	7,108	8,438
Stomach	Both Sexes	34,419	40,930	41,143	68,386	78,221
	Male	20,553	24,756	24,854	38,804	44,783
	Female	13,866	16,174	16,289	29,582	33,438
Colon & Rectum	Both Sexes	405,797	469,194	478,203	1,111,907	1,239,920
	Male	205,558	237,798	242,129	548,761	608,653
	Female	200,239	231,396	236,074	563,146	631,267
Liver & Intrahepatic Bile Duct	Both Sexes	26,017	29,875	29,931	35,119	39,545
	Male	18,881	21,432	21,488	24,549	27,385
	Female	7,136	8,443	8,443	10,570	12,160
Pancreas	Both Sexes	28,875	35,140	35,140	37,971	45,129
	Male	14,376	17,768	17,768	18,446	22,163
	Female	14,499	17,372	17,372	19,525	22,966
Larynx	Both Sexes	30,294	36,780	37,134	86,894	97,654
	Male	24,153	29,235	29,544	69,765	77,999
	Female	6,141	7,545	7,590	17,129	19,655
Lung & Bronchus	Both Sexes	224,508	284,065	291,615	379,223	462,713
	Male	104,519	133,787	136,648	173,619	212,377
	Female	119,989	150,278	154,967	205,604	250,336
Melanoma of the Skin	Both Sexes	263,883	297,561	309,968	837,215	901,518
	Male	140,746	162,207	170,141	415,003	452,508
	Female	123,137	135,354	139,827	422,212	449,010
Breast	Female	818,223	883,935	937,301	2,681,040	2,841,885
Cervix	Female	37,983	39,767	39,882	202,962	208,595
Corpus & Uterus, NOS	Female	160,329	180,638	180,713	553,870	603,503
Ovary ^f	Female	55,497	64,242	64,294	164,877	185,160

^a U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 34 years (1975-2008)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2004-2008)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2004; Melanoma in 2005.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 34-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2009.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 34-year limited duration prevalence. The 2004 breast cancer is counted for the breast 5-year and 34-year limited duration prevalence.

In method (e) the 2004 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2005 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2009^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			34-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 34 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 34 Years ^d
Prostate	Male	991,610	1,069,850	1,069,879	2,494,988	2,659,051
Testis	Male	41,292	42,052	42,698	194,935	197,533
Urinary Bladder	Both Sexes	196,403	243,253	248,175	540,518	626,417
	Male	148,936	185,112	189,064	402,281	466,103
	Female	47,467	58,141	59,111	138,237	160,314
Kidney & Renal Pelvis	Both Sexes	137,327	166,272	168,023	309,168	359,955
	Male	82,513	101,559	102,846	182,285	214,227
	Female	54,814	64,713	65,177	126,883	145,728
Brain & Nervous System	Both Sexes	42,492	44,665	45,128	121,848	125,138
	Male	23,270	24,518	24,750	64,666	66,457
	Female	19,222	20,147	20,378	57,182	58,681
Thyroid	Both Sexes	150,696	166,265	166,781	456,180	484,996
	Male	33,895	39,037	39,179	99,597	108,060
	Female	116,801	127,228	127,602	356,583	376,936
Hodgkin Lymphoma	Both Sexes	37,947	40,392	40,402	161,071	165,355
	Male	20,359	21,735	21,735	83,458	85,731
	Female	17,588	18,657	18,667	77,613	79,624
Non-Hodgkin Lymphoma	Both Sexes	193,568	226,608	228,204	474,455	529,222
	Male	101,809	120,766	121,658	246,926	276,020
	Female	91,759	105,842	106,546	227,529	253,202
Myeloma	Both Sexes	45,747	53,626	53,674	70,950	81,089
	Male	24,230	28,956	28,992	38,319	44,359
	Female	21,517	24,670	24,682	32,631	36,730
Leukemia	Both Sexes	108,472	124,139	124,315	266,026	291,521
	Male	62,188	71,959	72,042	150,062	165,245
	Female	46,284	52,180	52,273	115,964	126,276
Acute Lymphocytic Leukemia	Both Sexes	15,984	16,396	16,396	62,732	63,353
	Male	9,278	9,448	9,448	34,732	34,950
	Female	6,706	6,948	6,948	28,000	28,403
Childhood (Ages 0-19)	Both Sexes	61,498	61,622	62,135	288,648	289,141
	Male	32,966	33,016	33,253	148,843	149,048
	Female	28,532	28,606	28,882	139,805	140,093
Kaposi Sarcoma	Both Sexes	7,129	7,546	7,546	23,623	24,764
	Male	6,715	7,047	7,047	22,336	23,276
	Female	414	499	499	1,287	1,488
Mesothelioma	Both Sexes	3,040	3,957	3,957	4,570	5,673
	Male	2,095	2,759	2,759	2,694	3,484
	Female	945	1,198	1,198	1,876	2,189

^a U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

- ^c (c) First invasive tumor ever
 - ^d (d) First invasive tumor for each cancer site diagnosed during the previous 34 years (1975-2008)
 - ^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2004-2008)
- For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2004; Melanoma in 2005.
 In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 34-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2009.
 In method (d) the 1981 melanoma is counted for the melanoma and all sites 34-year limited duration prevalence. The 2004 breast cancer is counted for the breast 5-year and 34-year limited duration prevalence.
 In method (e) the 2004 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2005 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.22
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2009^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	5,809,017	18,156	41,323	80,500	150,710	346,280	815,636	1,465,844	2,890,567
Females	6,740,016	15,649	35,203	83,134	219,550	622,449	1,226,028	1,600,054	2,937,950
Oral Cavity & Pharynx									
Males	172,502	67	418	1,505	3,416	14,153	41,881	49,752	61,309
Females	91,610	101	493	1,453	3,530	8,334	17,445	21,205	39,049
Esophagus									
Males	24,657	0	0	38	186	1,059	4,426	8,360	10,588
Females	7,170	0	0	0	39	314	1,070	1,656	4,091
Stomach									
Males	39,694	0	17	78	688	2,436	6,519	9,680	20,275
Females	30,232	4	11	165	643	2,169	4,233	5,764	17,243
Colon & Rectum									
Males	558,408	11	69	1,116	5,277	24,270	77,071	129,789	320,804
Females	581,302	0	86	1,202	5,090	22,495	64,292	107,339	380,797
Liver & Intrahep									
Males	24,615	438	554	494	438	1,581	8,481	7,111	5,516
Females	10,913	466	435	332	473	786	2,384	2,609	3,430
Pancreas									
Males	18,537	0	23	68	321	1,356	4,100	5,731	6,939
Females	19,649	0	47	135	418	1,377	3,454	5,181	9,036
Larynx									
Males	71,550	0	0	66	221	2,095	10,475	20,267	38,425
Females	17,521	0	0	48	143	1,051	3,163	4,474	8,642
Lung & Bronchus									
Males	178,447	45	80	454	1,086	5,587	24,209	52,348	94,640
Females	209,203	34	47	363	1,291	7,893	27,437	57,808	114,331
Melanoma of the Skin									
Males	427,519	72	764	5,002	17,503	47,272	91,489	111,843	153,573
Females	448,192	95	950	10,770	33,163	72,253	104,576	99,252	127,133

^a U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 34 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2009^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	14,303	0	0	22	103	498	2,093	3,896	7,691
Females	2,747,209	0	86	2,487	35,584	212,685	522,225	733,979	1,240,161
Cervix									
Females	247,556	0	68	2,050	16,434	42,782	59,350	52,979	73,893
Corpus & Uterus, NOS									
Females	589,789	0	56	412	5,572	24,294	82,675	148,774	328,006
Ovary ^d									
Females	182,710	66	932	3,503	6,560	19,171	39,536	45,524	67,418
Prostate									
Males	2,496,420	34	69	89	247	19,652	216,595	687,644	1,572,090
Urinary Bladder									
Males	411,161	56	110	595	2,405	11,643	42,320	94,909	259,122
Females	143,089	34	56	162	1,087	4,412	13,373	29,661	94,303
Kidney & Renal Pelvis									
Males	188,341	1,507	2,373	2,601	4,936	16,313	37,165	53,360	70,087
Females	131,799	1,408	2,607	2,769	4,642	11,613	22,637	30,925	55,198
Hodgkin Lymphoma									
Males	90,420	168	2,316	9,264	16,301	23,466	20,120	12,217	6,567
Females	84,475	146	1,642	9,767	16,451	22,548	18,024	9,302	6,597
Non-Hodgkin Lymphoma									
Males	252,012	810	3,472	7,162	12,801	28,228	49,236	62,729	87,574
Females	232,051	387	1,793	4,203	8,302	19,927	39,219	53,951	104,268
Myeloma									
Males	38,403	0	6	50	485	2,628	7,535	12,343	15,356
Females	32,754	0	0	22	276	2,112	5,612	9,822	14,911
Leukemia									
Males	152,597	6,389	12,636	11,647	10,425	12,678	20,796	29,694	48,332
Females	119,096	5,232	10,502	10,167	9,042	9,418	13,463	19,494	41,777
Acute Lymphocytic Leuk									
Males	36,576	5,244	10,969	9,000	5,888	3,114	1,140	773	448
Females	29,614	4,381	8,829	7,398	4,995	2,241	767	687	315

^a U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 34 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.